Literature DB >> 8874182

Thrombopoietin, but not erythropoietin promotes viability and inhibits apoptosis of multipotent murine hematopoietic progenitor cells in vitro.

O J Borge1, V Ramsfjell, O P Veiby, M J Murphy, S Lok, S E Jacobsen.   

Abstract

The recently cloned c-mpl ligand, thrombopoietin (Tpo), has been extensively characterized with regard to its ability to stimulate the growth, development, and ploidy of megakaryocyte progenitor cells and platelet production in vitro and in vivo. Primitive hematopoietic progenitors have been shown to express c-mpl, the receptor for Tpo. In the present study, we show that Tpo efficiently promotes the viability of a subpopulation of Lin-Sca-1+ bone marrow progenitor cells. The ability of Tpo to maintain viable Lin-Sca-1+ progenitors was comparable to that of granulocyte colony-stimulating factor and interleukin-1, whereas stem cell factor (SCF) promoted the viability of a higher number of Lin-Sca-1+ progenitor cells when incubated for 40 hours. However, after prolonged (> 40 hours) preincubation, the viability-promoting effect of Tpo was similar to that of SCF. An increased number of progenitors surviving in response to Tpo had megakaryocyte potential (37%), although almost all of the progenitors produced other myeloid cell lineages as well, suggesting that Tpo acts to promote the viability of multipotent progenitors. The ability of Tpo to promote viability of Lin-Sca-1+ progenitor cells was observed when cells were plated at a concentration of 1 cell per well in fetal calf serum-supplemented and serum-depleted medium. Finally, the DNA strand breakage elongation assay showed that Tpo inhibits apoptosis of Lin-Sca-1+ bone marrow cells. Thus, Tpo has a potent ability to promote the viability and suppress apoptosis of primitive multipotent progenitor cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8874182

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  11 in total

Review 1.  Piecing together the humoral and cellular mechanisms of immune thrombocytopenia.

Authors:  Lisa J Toltl; Ishac Nazi; Reza Jafari; Donald M Arnold
Journal:  Semin Thromb Hemost       Date:  2011-11-18       Impact factor: 4.180

Review 2.  Hematopoietic stem cell gene therapy:assessing the relevance of preclinical models.

Authors:  Andre Larochelle; Cynthia E Dunbar
Journal:  Semin Hematol       Date:  2013-04       Impact factor: 3.851

3.  Cytokines regulate postnatal hematopoietic stem cell expansion: opposing roles of thrombopoietin and LNK.

Authors:  Natalija Buza-Vidas; Jennifer Antonchuk; Hong Qian; Robert Månsson; Sidinh Luc; Sasan Zandi; Kristina Anderson; Satoshi Takaki; Jens M Nygren; Christina T Jensen; Sten Eirik W Jacobsen
Journal:  Genes Dev       Date:  2006-08-01       Impact factor: 11.361

Review 4.  The biology of thrombopoietin and thrombopoietin receptor agonists.

Authors:  David J Kuter
Journal:  Int J Hematol       Date:  2013-07-03       Impact factor: 2.490

5.  The non-peptide thrombopoietin receptor agonist eltrombopag stimulates megakaryopoiesis in bone marrow cells from patients with relapsed multiple myeloma.

Authors:  Jee-Yeong Jeong; Michelle S Levine; Nirmalee Abayasekara; Nancy Berliner; Jacob Laubach; Gary J Vanasse
Journal:  J Hematol Oncol       Date:  2015-04-16       Impact factor: 17.388

Review 6.  Anti-apoptotic BCL-2 family members in development.

Authors:  Joseph T Opferman; Anisha Kothari
Journal:  Cell Death Differ       Date:  2017-11-03       Impact factor: 15.828

Review 7.  Hematopoietic stem cells: ex-vivo expansion and therapeutic potential for myocardial ischemia.

Authors:  Jingwei Lu; Vincent J Pompili; Hiranmoy Das
Journal:  Stem Cells Cloning       Date:  2010-03-30

8.  The thrombopoietin receptor, c-Mpl, is a selective surface marker for human hematopoietic stem cells.

Authors:  John M Ninos; Leigh C Jefferies; Christopher R Cogle; William G Kerr
Journal:  J Transl Med       Date:  2006-02-16       Impact factor: 5.531

9.  Functional Cooperativity between ABCG4 and ABCG1 Isoforms.

Authors:  Zoltán Hegyi; László Homolya
Journal:  PLoS One       Date:  2016-05-26       Impact factor: 3.240

10.  Thrombopoietin is required for full phenotype expression in a JAK2V617F transgenic mouse model of polycythemia vera.

Authors:  Jerry L Spivak; Akil Merchant; Donna M Williams; Ophelia Rogers; Wanke Zhao; Amy Duffield; Linda S Resar; Alison R Moliterno; Zhizhuang J Zhao
Journal:  PLoS One       Date:  2020-06-01       Impact factor: 3.752

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.